SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending sharply higher after President Trump announced a "framework" deal with NATO regarding Greenland and unexpectedly reversed course on potential new tariffs against Europe. This geopolitical de-escalation is sparking a significant market rally, with many traders labeling it a "TACO" (Trump Always Chickens Out) trade as market fears rapidly dissipate. Community discussion highlights the immediate bullish reaction, while some question the broader implications of such swift policy reversals on market stability.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing significant activity as President Trump's announcement of a Greenland "framework" and the suspension of EU tariffs fueled a rapid market rebound. Traders are actively discussing the "TACO trade," where initial geopolitical uncertainty quickly reversed, leaving bears burned and reinforcing the "buy the dip" strategy amidst perceived market manipulation. This volatility underscores how headline-driven events continue to create dramatic swings in market sentiment.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a new licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community sees as a major validation for its platform. Investors are keenly discussing the potential for a substantial short squeeze, fueled by high short interest and expectations of more partnerships for Matrix-M as a multi-billion dollar asset.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending amid high community discussion regarding its Anktiva immunotherapy, with optimism fueled by anticipated FDA advancements for bladder cancer and recent international regulatory wins. Investors are actively debating a potential short squeeze, given the substantial short interest and rising borrow costs, while also highlighting the company's ambitious goal to revolutionize cancer treatment. The broader context of global approvals and a strong product pipeline sustains a bullish outlook despite market volatility.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is generating significant buzz as investors keenly follow recent U.S. regulatory updates, including streamlined deep-sea mining permit processes and an upcoming Congressional hearing featuring TMC's CEO. The community anticipates a major breakout, driven by increasing recognition of deep-sea minerals as a national security priority and the potential for expedited commercial recovery.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively discussed amidst evolving geopolitical developments surrounding Greenland's rare earth mineral rights, particularly following recent statements from former President Trump and upcoming business updates. Investors are closely watching for definitive outcomes, with many anticipating a significant boost from any potential deal securing U.S. access to Greenland's vast critical metal deposits, despite notable short-term volatility and accusations of market manipulation.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant volatility following Donald Trump's comments from Davos, which included remarks on tariffs and crypto legislation. The community remains fiercely divided, with some anticipating a major short squeeze and new all-time highs, while others warn of institutional manipulation and potential bear traps amid the turbulent price action.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is currently trending after its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This news has ignited intense community discussion, with traders anticipating a potential short squeeze and substantial upside given the stock's low float and the expanded market access within the VA healthcare system. Many are celebrating significant gains and drawing comparisons to other recently volatile low-float plays.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending due to a significant partnership with Primary Digital Infrastructure for a massive AI data center campus in West Texas, coupled with a key acquisition. The community is actively discussing strong price action and anticipating an imminent announcement regarding a hyperscaler tenant, fueling speculation of continued upward momentum and a potential short squeeze within the burgeoning AI infrastructure sector.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is fueling intense market debate following an extraordinary, near-parabolic rally driven by surging demand for memory and data storage, particularly from the AI infrastructure sector, amidst tight supply. While many celebrate its astronomical gains and anticipate further upside, a vocal group warns of an unsustainable bubble nearing a dramatic correction. The divergence of opinion creates a highly charged environment as traders watch for signs of exhaustion or continued momentum.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways.</li><li>The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.</li><li>Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.</li></ul>Enveric Biosciences Inc. (SOPA) shares gained over 7% in Monday’s pre-market trade after the company announced that it has been issued a patent that covers novel molecules with likely applications for the treatment of neuropsychiatric conditions.The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Licensing Opportunity</h2>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways. The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.<h2 class="st-heading-2">Patent Details</h2>Enveric stated that the molecules covered by this patent are based on known compounds with relevant pharmacological activity. It added that these compounds are chemically altered to improve efficacy while reducing side effects compared to existing compounds.“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Enveric CEO Joseph Tucker.Enveric is a Massachusetts-based biotechnology company focused on developing small-molecule neuroplastogenic therapeutics for the treatment of psychiatric and neurological disorders.<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 99.6% year-to-date and 99.5% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paul-krugman-warns-2026-worse-for-small-businesses/cL75twFRExT">Paul Krugman Warns 2026 Will Be Worse For Small Businesses, A Month After Small Firms Cut 120,000 Jobs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ENVB Stock Rising Today?

The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.

Equity

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

<ul class="summary-bullets"><li>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted.</li><li>By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space.</li><li>Enveric’s stock surged 106% in Wednesday’s premarket.</li></ul>Enveric Biosciences (ENVB) stock is drawing investors' attention on Wednesday after the company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application covering its EVM301 Series of molecules.<a href="https://stocktwits.com/symbol/ENVB/sentiment">Enveric’s stock</a> traded over 106% higher in Wednesday’s premarket.&nbsp;<h2 class="st-heading-2">Patent Focus and Potential</h2>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted, providing Enveric with intellectual property protection for its neuroplastogenic compounds.“We believe EB-003 holds great potential as the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects, while being specifically designed to promote neuroplasticity and minimize hallucinogenic effects, allowing administration in outpatient setting,” said Joseph Tucker, CEO, Enveric.&nbsp;By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space, particularly for patients with limited therapeutic options. The patent also enhances the company’s ability to pursue future research and commercialization of its EVM301 compounds.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>The stock was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:936/103;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_10_090740_png_d70c080d0b.webp" alt="ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits" width="936" height="103"><figcaption>ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said that if the drug proves safe and effective, a potential buyout exceeding $1 billion could be possible.&nbsp;<stembedurl>https://stocktwits.com/Luckyjs38/message/638708222</stembedurl>Another user expressed optimism about the low float and fresh IP update.&nbsp;<stembedurl>https://stocktwits.com/Caicong/message/638709397</stembedurl>ENVB stock has lost over 90% of its value year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-beat-stock-rocket-72-in-pre-market-today/cLIH2RhREV2">Why Did BEAT Stock Rocket 72% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various substances are placed on cooling blocks in the PCR laboratory of the State Office for Agriculture, Food Safety and Fisheries.

Why Did ENVB Stock More Than Double In Value Today?

The company received a Notice of Allowance from the United States Patent and Trademark Office for its patent application.

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During J.P. Morgan Week 2026

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders...

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$4.15
Prev Close	$4.04
Open	$4.08
Dividend Yield	0.00%
50-Day Moving Average	$5.19
Beta	1.22
Avg. Volume	1.88M
PE Ratio	-0.04

52-Week High	$63.00
52-Week Low	$3.50
Market Capitalization	$4.13M
EPS (Annual)	-$228.48
Price to Book	0.61
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ENVB
Enveric Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ENVB News

ENVBEnveric Biosciences Inc